

## COVID-19 Survivors' Reports of the Timing, Duration, and Health Impacts of Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection

Natalie Lambert, PhD;<sup>1</sup> Survivor Corps; Sarah A. El-Azab, MS;<sup>2</sup> Nathan S. Ramrakhiani,<sup>3</sup> Anthony Barisano,<sup>3</sup> Lu Yu,<sup>4</sup> Kaitlyn Taylor,<sup>5</sup> Alvaro Esperanca,<sup>6</sup> Charles A. Downs,<sup>7</sup> Heather L. Abraham,<sup>8</sup> Melissa D. Pinto,<sup>8</sup> Rana Chakraborty,<sup>9</sup> & Jessica L. Borelli<sup>10</sup>

### Affiliations:

<sup>1</sup>Indiana University School of Medicine, Department of Biostatistics and Health Data Sciences; <sup>2</sup>University of Michigan, Department of Health Management and Policy; <sup>3</sup>Brown University, Providence, RI; <sup>4</sup>University of Illinois at Urbana-Champaign, School of Labor and Employment Relations; <sup>5</sup>Indiana University School of Medicine, Lambert Health Lab; <sup>6</sup>Indiana University Purdue University Indianapolis, Electrical and Computer Engineering Department; <sup>7</sup>University of Miami, School of Nursing & Health Studies, Coral Gables, Florida; <sup>8</sup>University of California Irvine, Sue & Bill Gross School of Nursing, Irvine California; <sup>9</sup>Mayo Clinic, Division of Infectious Disease, Department of Pediatrics and Adolescent Medicine, Rochester, Minnesota; <sup>10</sup>University of California, Irvine, Department of Psychological Science

\*Corresponding author: Natalie Lambert, PhD, 410 W. 10th St., Indianapolis, IN 46202  
Email: nalamb@iu.edu

Abstract: 420 words, Text: 1915 words, References: 15, Figures: 4, Tables: 2

### Abstract

**IMPORTANCE:** Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) is a major public health concern. Studies suggest that 1 in 3 infected with SARS-CoV-2 may develop PASC, including those without initial symptoms or with mild COVID-19 disease.<sup>1,2</sup>

**OBJECTIVE:** To evaluate the timing, duration, and health impacts of PASC reported by a large group of primarily non-hospitalized COVID-19 survivors.

**DESIGN, SETTING, AND PARTICIPANTS:** A survey of 5,163 COVID-19 survivors reporting symptoms for more than 21 days following SARS-CoV-2 infection. Participants were recruited from Survivor Corps and other online COVID-19 survivor support groups.

**MAIN OUTCOMES AND MEASURES:** Participants reported demographic information, as well as the timing, duration, health impacts, and other attributes of PASC. The temporal distribution of symptoms, including average time of onset and duration of symptoms were determined, as well as the perceived distress and impact on ability to work.

**RESULTS:** On average, participants reported 21.4 symptoms and the number of symptoms ranged from 1 to 93. The most common symptoms were fatigue (79.0%), headache (55.3%), shortness of breath (55.3%), difficulty concentrating (53.6%), cough (49.0%), changed sense of taste (44.9%), diarrhea (43.9%), and muscle or body aches (43.5%). The timing of symptom onset varied and was best described as happening in waves. The longest lasting symptoms on average for all participants (in days) were “frequently changing” symptoms (112.0), inability to exercise (106.5), fatigue (101.7), difficulty concentrating (101.1), memory problems (100.8), sadness (99.2), hormone imbalance (99.1), and shortness of breath (96.9). The symptoms that affected ability to work included the relapsing/remitting nature of illness (described by survivors as “changing symptoms”), inability to concentrate, fatigue, and memory problems, among others. Symptoms causing the greatest level of distress (on scale of 1 “none” to 5 “a great deal”) were extreme pressure at the base of the head (4.4), syncope (4.3), sharp or sudden chest pain (4.2), brain pressure (4.2), headache (4.2), persistent chest pain or pressure (4.1), and bone pain in extremities (4.1).

**CONCLUSIONS AND RELEVANCE:** PASC is an emerging public health priority characterized by a wide range of changing symptoms, which hinder survivors’ ability to work. PASC has not been fully characterized and the trajectory of symptoms and long-term outcomes are unknown. There is no treatment for PASC, and survivors report distress in addition to a host of ongoing symptoms. Capturing patient reports of symptoms through open-ended inquiry is a critical first step in accurately and comprehensively characterizing PASC to ensure that medical treatments and management strategies best meet the needs of individual patients and help mitigate health impacts of this new disease.

## Introduction

The long-term effects of infection with SARS-CoV-2 are poorly understood. This is particularly alarming given that over 118,000,000 persons have contracted SARS-CoV-2 since the virus emerged in late 2019.<sup>3</sup> Recent studies suggest that nearly a third of individuals having had SARS-CoV-2 infection, including those who are initially asymptomatic, go on to develop symptoms that appear to last for a yet undefined period of time.<sup>1</sup> These COVID-19

survivors report a wide range of long-lasting sequelae,<sup>4</sup> some of which are ongoing nine months after infection.<sup>5</sup>

To date most of the research involving SARS-CoV-2 and its consequences has involved the 10% of individuals with severe illness that required hospitalization,<sup>6-8</sup> leaving a significant gap in our understanding of the health impacts of SARS-CoV-2 infection among the majority (90%) of persons who have been infected to date – those that did not require hospitalization. As data emerged, persons with persistent symptoms 21 or more days following infection have been labeled as "long-haulers," or those with Post-Acute Sequelae of SARS-CoV-2 (PASC). Not only is public awareness surrounding this topic low, but research concerning PASC is minimal.<sup>9</sup> Here, we characterize PASC among a participant group composed primarily of non-hospitalized COVID-19 survivors (n=5,163) through a survey that captures symptom timing, duration, and health impacts of PASC.

## Methods

Data for this project were procured through an IRB-approved study and was made possible by a collaboration between the Indiana University School of Medicine and Survivor Corps. Survivor Corps is a COVID-19 grassroots organization and Facebook group dedicated to supporting COVID-19 survivors and scientific research of COVID-19. In August 2020, a REDCap survey was disseminated to Survivor Corps group members on Facebook and in other online COVID-19 groups. The survey was sent out again in November 2020 to collect more data. The purpose of the survey was to understand respondents' experiences with the timing and duration of the COVID-19 symptoms and how they were impacted by these symptoms.

To participate in the study, all respondents had to be 18 years or older and have been diagnosed with COVID-19 through a positive SARS-CoV-2 antigen or RT PCR test, physician diagnosis, self-diagnosis, or some other method (e.g., positive antibody test). The survey collected self-reported demographic information, an extensive medical history (including underlying conditions), and experiences with COVID-19 (including hospitalization). In addition, the survey listed and asked questions about 101 distinct

COVID-19 symptoms and gave respondents the option to report additional symptoms they had experienced that were not listed. The initial survey collected 5,875 responses.

All survey data were manually reviewed and cleaned for analysis. While asymptomatic respondents could participate, only data from respondents who reported symptoms were included in the results. To focus on the experiences of people with PASC, the data analyzed were further limited to respondents who had experienced symptoms for longer than 21 days. The final dataset for analysis consisted of 5,163 participants.

For each symptom, the percentage of participants reporting the symptom, average pain or discomfort associated with the symptom, average duration, and average time to symptom onset were calculated. Means were calculated for participants' responses to a 5-point Likert scale from "Not at all" to "Very much" for questions about the pain and discomfort, work impairment, and social relationship impact caused by each symptom. Additionally, the percentage of participants that reported the symptom as ongoing and the percentage who reported the symptom as intermittent was calculated for each symptom. The ggplot R package was used to visualize the relationship between symptom discomfort and average duration, the distribution of the number of symptoms reported by each participant, and to create a table containing all symptom metrics calculated for this study.

## **Results**

### ***Survey demographics***

A total of 5,875 people responded to the survey. Of these, 5,163 reported persistent symptoms. Participants were predominantly White (81.3%), female (85.7%), never hospitalized for COVID-19 (89.3%), and received either a provider diagnosis or RT-PCR confirmed SARS-CoV-2 infection (77.1%). See Table 1 for more detail.

### ***Prevalence and duration of symptoms among participants with PASC***

PASC individuals reported an average of 21.4 symptoms with a range of 1 to 93 symptoms occurring (*Supplemental Figure 1*). The prevalence of symptoms is reported in Figure 1, and a graph of combined average time to symptom onset and duration among participants with PASC is reported in Figure 2. Of the 101 symptoms reported, the most

prevalent symptoms included fatigue, headache, shortness of breath, difficulty concentrating, inability to exercise, cough, change in sense of taste, diarrhea, and muscle or body aches. Timing of symptom onset varied and was typically described as occurring in “waves”. Symptom duration ranged from 2 weeks to over 100 days, with changing symptoms being a prominent, long-lasting feature (Figure 2). The first wave (arrhythmia to burning calves) appeared to be heavily dominated by neurological and cardiovascular manifestations with some indicators of a strong immune response (enlarged and painful lymph nodes), followed by microvascular consequences in the second wave (Covid toes). The final wave suggested impact on endocrine (thyroid) function. At the time that they took the survey 98.0% of the respondents said they had symptoms that were unresolved, and 97.8% reported that at least one of their symptoms was intermittent, meaning it would temporarily resolve and then later return.

### ***Impact of symptoms on participants with PASC***

The calculations of average time to symptom onset; symptom duration; percentage of respondents who reported the symptom as intermittent or ongoing; and the average symptom impact in terms of pain and discomfort, work impairment, and social relationship are recorded in Table 2. Variables included percentage reporting a symptom; pain and discomfort of the symptom (e.g., distress); ability to work or socialize; symptom duration; percentage reporting ongoing symptoms; and percentage reporting symptoms as intermittent. Potential morbidity, especially inability to work, was assessed through symptom severity, duration, and perceived impact on ability to work (Figure 3).

Symptoms perceived to have the most impact on ability to work included fatigue, personality change, a sensation of “brain pressure”, inability to sleep, inability to exercise, difficulty concentrating, memory problems, confusion, shortness of breath, and the relapsing/remitting nature of symptoms.

## **Conclusions**

The current study provides much needed insight into the sequelae of acute SARS-CoV-2 infection. These findings warrant additional discussion, investigation, and context within the current knowledge of PASC. In reviewing our findings, we believe there are 4 key take-

away points that warrant further discussion.

First, the fact that survey participants reported an average of 24.1 symptoms means that the average PASC patient experiences more long-lasting sequelae of COVID-19 than is currently captured by most research studies.<sup>10, 11</sup> The study's ability to detect a larger number of symptoms can be attributed to including a list of potential COVID-19 symptoms based on initial open-ended research of the range of COVID-19 sequelae conducted in July of 2020<sup>4</sup> and expanded through feedback on the survey design from Survivor Corps. Strengths of this study include reporting of symptoms among the 5,163 individuals who have and are continuing to experience symptoms up to a year after SARS-CoV-2 infection, (PASC survivors). Participants were able to describe their symptoms and health impact caused by these symptoms in detail, which provides additional richness and insight into the symptom sequelae.

A second insight was that PASC may affect more women than men since 85.7% of our PASC respondents were women. Although prior research has found that older adults are at greater risk of hospitalization than younger adults, in our participant group PASC impacted people in the middle years of life most frequently with 77.0% (n= 3,980) of our participants aged 35-64. We<sup>2</sup> and others<sup>8, 12, 13</sup> have shown that PASC occurs more frequently in women with an age distribution similar to this study. Our participants were also largely not hospitalized, indicating a less severe initial course. 77% of participants reported clinician diagnosis or confirmed RT PCR for SARS-CoV-2, with 5% reporting "other" and ~18% self-diagnosing. Those without confirmed diagnosis may have attributed SARS-CoV-2 infection with a confirmed antibody test that was available early in the pandemic or through the presence of COVID-specific symptoms such as loss of sense of smell. While there may be an inclination for researchers to exclude participants who do not have a positive RT PCR or antibody test from COVID-19 research, capturing the experiences of the earliest long haulers (before validated tests had become available) is essential for understanding the trajectory of PASC.

Third, participants reported multiple symptoms that appear to occur in waves. This observation is consistent with other reports, including hospitalized individuals. The temporal nature of these symptoms may provide clues into underlying pathophysiology, which is currently unclear. Others describe PASC symptoms occurring in waves which may indicate an evolving process guided by endothelial dysfunction, inflammation, oxidative stress, and

hormonal imbalance.<sup>14,15</sup> However, a causal relationship has not been established. These findings align with the team's prior work in different data sets that observed medically documented symptoms in electronic health records longitudinally and established a temporal order and inclusion of only new symptoms at 0-11 and 60+days following a positive SARS-CoV-2 PCR test. In this work we identified 5 symptom clusters in non-hospitalized PASC survivors, with dominant symptoms in those clusters all represented in the top quartile of symptoms reported here. Of note is the changing nature of symptoms, which appears to be a particularly distressing feature among PASC survivors.

Finally, PASC appears to exert variable degrees of impact on individuals, but mechanistic insight is lacking. Most studies to date have focused on hospitalized patients; however, in our study most participants were never hospitalized, suggesting that PASC has profound effects, independent of COVID-19 severity. Factors that were reported to have the most impact on participants' ability to work after developing PASC included the relapsing/remitting nature of symptoms, the long duration of many symptoms reported as unresolved, as well as fatigue and symptoms associated with altered cognition or memory impairment. Overall, reported symptoms varied with regards to duration and for their degree of distress, suggesting that a symptom of PASC can cause severe health impacts for some and milder impacts for others, making PASC an experience that is unique to the individual. Considering the great number and severity of health impacts caused by PASC, future research with PASC patients should endeavor to collect qualitative data, asking patients to report on the lasting impacts including their ability to work, maintain social relationships, their mental health, as well as basic everyday functioning. Analysis and fusion of biological and qualitative data are essential to ensure that health policy can be designed to meet PASC survivors' needs.

### **Limitations**

The sequelae of acute SARS-CoV-2 infection are just beginning to be understood, and it is clear that PASC affects those who were never hospitalized for severe illness. More work is needed to corroborate our findings and to document the temporal nature of symptoms of PASC. Further research is needed to determine non-modifiable risk factors associated with increased risk of acquiring PASC, as well as aberrant innate and adaptive immune responses

associated with PASC.

## **Acknowledgements**

Thank you to Survivor Corps for mobilizing many thousands of COVID-19 survivors to participate in research to find a cure for COVID-19, and for being the epicenter of hope for so many. We would like to express our deep gratitude to the thousands of long haulers who spent many hours taking this survey while suffering from the impacts of PASC. The answers we need to cure PASC will come from listening and learning from those who suffer from the disease.

We would also like to thank the Precision Health Initiative at Indiana University for their support on this project.



## Table and Figure Legends

**Table 1. Participant demographics.** Table showing distribution of participants based on race and ethnicity, gender, age, mode of determining SARS-CoV-2 infection, and hospitalization status.

**Table 2: COVID-19 symptoms and their health impacts.** Health impact variables include: percentage of participants reporting symptoms, pain and discomfort (e.g. level of distress), ability to work, social impairment, symptom duration, percentage reporting symptoms as ongoing, and percentage reporting symptoms as intermittent.

**Figure 1: Percentage of respondents reporting each COVID-19 symptom.** Graph showing percentage of participants (*x*-axis) who experienced a given symptom (*y*-axis).

**Figure 2. Average symptom onset and duration.** Graph plotting the average time of symptom onset (in days after initial infection date) with average symptom duration. \*Duration measures length of time the symptom was present and does not indicate resolution of the symptom. Participants noted these symptoms were ongoing at the time they completed the survey.

**Figure 3. Impact of level of distress and duration of symptoms on ability to work among PASC survivors.** Graph showing the effect of duration of symptoms (*x*-axis) and level of distress (*y*-axis) on ability to work. Darker shades indicate greater impact on ability to work.

**Supplemental Figure 1. Distribution of the number of symptoms reported by participants.** Graph visualizing the distribution of the number of symptoms reported by survey participants.

## References

1. Nehme M, Braillard O, Alcoba G, et al. COVID-19 Symptoms: Longitudinal Evolution and Persistence in Outpatient Settings. *Ann Intern Med*. [Epub ahead of print 8 December 2020].doi:10.7326/M20-5926
2. Huang, Y, Pinto, MD, Borelli, JL, et al. COVID Symptoms, Symptom Clusters, and Predictors for Becoming a Long-Hauler: Looking for Clarity in the Haze of the Pandemic. medRxiv 2021.03.03.21252086; doi: <https://doi.org/10.1101/2021.03.03.21252086>
3. Johns Hopkins University of Medicine. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Johns Hopkins University of Medicine Coronavirus Resource Center. January 22, 2020. Accessed March 9, 2021. <https://coronavirus.jhu.edu/map.html>
4. Lambert, N. J. & Survivor Corps COVID-19 “Long Hauler” Symptoms Survey Report. *Indiana University School of Medicine*. Published online July 7, 2020. Accessed March 19, 2021. <https://static1.squarespace.com/static/5e8b5f63562c031c16e36a93/t/5f459ef7798e8b6037fa6c57/1598398215120/2020+Survivor+Corps+COVID-19+%27Long+Hauler%27+Symptoms+Survey+Report+%28revised+July+25.4%29.pdf>
5. Logue JK, Franko NM, McCulloch DJ, et al. Sequelae in Adults at 6 Months After COVID-19 Infection. *JAMA Netw Open*. 2021;4(2):e210830. doi:10.1001/jamanetworkopen.2021.0830
6. Garrigues E , Janvier P , Kherabi Y , et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. *J Infect*. 2020;81(6):e4-e6. doi:10.1016/j.jinf.2020.08.029
7. Tenforde M, Kim S, Lindsell C, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet*. 2021;397(10270): 220-232. doi:10.1016/S0140-6736(20)32656-8
8. Carfi, A, Bernabei, R., Landi, F., et al. Persistent symptoms in patients after acute COVID-19. *JAMA*. 2020;324(6): 603-605. doi:10.1001/jama.2020.12603
9. Alwan NA. Surveillance is underestimating the burden of the COVID-19 pandemic. *Lancet*. 2020;396(10252): e24. doi:10.1016/S0140-6736(20)31823-7

10. Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69:993-998. DOI: <http://dx.doi.org/10.15585/mmwr.mm6930e1>
11. Stavem K, Ghanima W, Olsen MK, et al Persistent symptoms 1.5–6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study. *Thorax.* 2021;76:405-407.
12. Sudre, C.H., Murray, B., Varsavsky, T. et al. Attributes and predictors of long COVID. *Nat Med.* 2021. <https://doi.org/10.1038/s41591-021-01292-y>
13. Davido B, Seang S, Tubiana R, Truchis P. Post–COVID-19 chronic symptoms: a postinfectious entity?. *Clin Microbiol Infect.* 2020; 26(11): 1448-1449. <https://doi.org/10.1016/j.cmi.2020.07.028>
14. Theoharides TC, Conti P. COVID-19 and multisystem inflammatory syndrome, or is it mast cell activation syndrome?. *J Biol Regul Homeost Agents.* 2020 Sep 1;34(5).
15. Leung TYM, Chan AYL, Chan EW, et al. Short- and potential long-term adverse health outcomes of COVID-19: a rapid review. *Emerg Microbes Infect.* 2020; 9:1, 2190-2199, DOI: 10.1080/22221751.2020.1825914

**Table 1** Participant Demographics

CHARACTERISTIC	PARTICIPANTS (n=5163), No. (%)
<b>Race and Ethnicity:</b>	
White	4198 (81.3)
Hispanic or Latinx	330 (6.4)
Multiracial	159 (3.1)
Asian/Pacific Islander	114 (2.2)
Black	111 (2.2)
Hispanic or Latinx, White	89 (1.7)
Black	41 (0.8)
American Indian	35 (0.7)
Hispanic or Latinx, Multiracial	27 (0.5)
Other	22 (0.4)
Middle Eastern	19 (0.4)
Hispanic or Latinx, American Indian	7 (0.1)
Hispanic or Latinx, Black	6 (0.1)
Hispanic or Latinx, Other	3 (0.1)
Hispanic or Latinx, Asian/Pacific Islander	2 (0.0)
<b>Gender:</b>	
Female	4422 (85.7)
Male	714 (13.8)
Non-binary/non-conforming	15 (0.3)
Unknown	10 (0.2)
Transgender	2 (0.0)
<b>Age:</b>	
18-24	118 (2.2)
25-34	593 (11.5)
35-44	1298 (25.1)
45-54	1560 (30.2)
55-64	1122 (21.7)
65-74	428 (8.3)
75-84	40 (0.8)
85+	4 (0.1)
<b>COVID-19 Diagnosis:</b>	
Positive COVID-19 test	2644 (51.2)
Diagnosis from doctor	1337 (25.9)

Self-diagnosed based on symptoms	918 (17.8)
Other	264 (5.1)
<b>Hospitalized:</b>	
No	4918 (83.9)
Yes	876 (15.5)
NA	38 (0.6)

**Table 2** COVID-19 symptoms and their health impacts

Symptom	Number of patients reporting symptom	Percentage of patients reporting symptom (%)	Median start date (days)	Mean duration (days)	Average pain/discomfort of symptom (1-5)	Average work impairment of symptom (1-5)	Average social impairment of symptom (1-5)	Percentage afflicted reporting symptom as ongoing (%)	Percentage afflicted reporting symptom as intermittent (%)
Fatigue	4077	78.97	8.28	101.70	3.77	3.79	3.68	83.25	53.74
Headache	2856	55.32	9.67	75.58	4.15	3.22	3.07	65.90	76.68
Shortness of breath or difficulty breathing	2854	55.28	11.39	91.01	4.04	3.40	3.26	72.04	66.40
Difficulty concentrating or focusing	2766	53.57	17.05	101.11	3.14	3.66	3.18	83.41	69.99
Inability to exercise or be active	2559	49.56	10.17	106.51	3.84	3.48	3.60	84.25	32.00
Cough	2532	49.04	6.93	66.58	3.48	2.46	2.39	52.41	57.23
Changed sense of taste	2318	44.90	10.61	59.32	2.50	1.32	1.63	53.71	31.58
Diarrhea	2268	43.93	13.00	51.73	3.50	2.49	2.39	44.22	63.62
Muscle or body aches	2246	43.50	9.97	82.03	4.05	3.12	2.98	64.07	61.62
Difficulty sleeping	2159	41.82	17.36	95.81	3.59	3.35	3.16	80.45	50.58
Memory problems	2069	40.07	24.77	100.83	3.00	3.55	3.10	86.52	63.80
Heart palpitations	2038	39.47	24.61	86.23	3.51	2.90	2.74	76.55	84.69
Partial or complete loss of sense of smell	2036	39.43	8.38	58.23	2.50	1.47	1.71	48.33	22.94
Dizziness	1943	37.63	21.50	79.86	3.53	3.14	2.92	68.76	82.86
Fever or chills	1938	37.54	5.33	42.22	3.68	2.60	2.47	27.19	57.28
Partial or complete loss	1877	36.35	9.09	55.19	2.46	1.44	1.71	45.07	24.08

medRxiv preprint doi: <https://doi.org/10.1101/2021.03.22.21254026>; this version posted March 22, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

of sense of taste									
Bone aches in extremities	1804	34.94	16.64	79.27	4.12	2.97	2.88	73.61	69.90
Abdominal pain	1770	34.28	15.05	57.32	3.77	2.47	2.56	61.07	80.51
Anxiety	1764	34.17	17.68	92.70	3.60	3.15	3.39	88.72	83.84
Hair loss	1727	33.45	56.95	71.29	2.34	1.40	1.74	76.03	15.98
Persistent chest pain or pressure	1723	33.37	14.60	89.38	4.12	3.30	3.15	66.69	67.38
Confusion	1712	33.16	19.98	91.29	3.38	3.65	3.33	78.62	77.10
Tachycardia	1640	31.76	25.65	87.28	3.62	3.09	2.94	70.49	76.77
Congested or runny nose	1638	31.73	10.53	63.96	2.86	1.89	1.83	57.39	53.79
Joint pain	1598	30.95	20.18	92.04	4.06	3.15	3.04	76.47	62.08
Blurry vision	1577	30.54	30.01	86.17	2.98	2.69	2.21	79.71	71.85
Sleeping more than normal	1549	30.00	8.66	89.93	2.63	3.25	3.16	68.82	38.80
Sore throat	1535	29.73	10.25	55.58	3.28	2.09	2.02	43.06	52.44
Nausea or vomiting	1481	28.68	16.56	55.70	3.88	2.84	2.77	45.78	70.02
Chills but no fever	1478	28.63	12.52	58.02	3.30	2.24	2.19	42.69	77.13
Night sweats	1446	28.01	14.84	69.45	3.29	1.93	1.88	49.03	69.16
Shortness of breath or exhaustion from bending over	1280	24.79	18.03	96.91	3.80	3.37	3.15	76.17	55.55
Arrhythmia	1246	24.13	24.37	86.77	3.53	2.84	2.77	79.86	87.72
Neuropathy in hands and feet	1219	23.61	36.69	89.11	3.71	3.04	2.86	79.66	68.33
Feeling irritable	1207	23.38	23.35	90.79	3.06	2.85	3.36	79.45	77.96


Sadness	1168	22.62	23.12	99.16	3.44	3.04	3.48	79.54	69.26
Weight loss	1158	22.43	14.91	57.30	1.91	1.55	1.53	36.01	18.05
Changing symptoms	1157	22.41	16.49	112.04	3.93	3.61	3.61	83.49	82.45
Phlegm in back of throat	1150	22.27	17.48	90.22	2.86	1.90	1.85	71.83	54.87
Phantom smells	1137	22.02	39.29	73.49	2.14	1.43	1.54	64.82	81.71
Constant thirst	1001	19.39	17.05	77.87	2.63	1.74	1.66	67.43	43.96
Lower back pain	987	19.12	23.56	78.89	4.10	3.17	2.99	65.96	63.32
Brain pressure	980	18.98	21.56	82.40	4.22	3.56	3.42	73.16	78.27
Heat intolerance	948	18.36	35.20	92.86	3.70	2.83	3.03	83.23	51.58
Sharp or sudden chest pain	946	18.32	29.07	76.74	4.25	3.15	2.95	59.83	79.49
Clogged ears	923	17.88	26.24	76.74	3.12	2.19	2.17	70.21	63.06
Reflux	921	17.84	32.64	87.83	3.56	2.23	2.23	73.07	72.42
Burning sensations	901	17.45	30.22	78.29	3.71	2.64	2.58	70.26	81.69
Calf cramps	898	17.39	34.81	71.81	3.69	2.37	2.28	71.38	84.97
Hand or wrist pain	898	17.39	40.58	82.63	3.78	3.05	2.47	77.17	67.37
Weight gain	885	17.14	39.50	95.66	2.72	1.81	2.11	82.94	15.14
Neck muscle pain	874	16.93	25.46	76.40	4.00	3.07	2.85	66.48	58.81
Tremors	869	16.83	29.66	76.00	3.35	3.05	2.75	66.28	76.18
Tinnitus	864	16.73	36.60	93.02	3.01	2.13	2.08	75.35	60.19
Ear pain or ear ache	863	16.72	26.75	67.91	3.51	2.35	2.23	58.98	69.06
Rash	821	15.90	39.12	58.84	2.91	1.84	1.87	46.41	46.04
Extreme	817	15.82	21.51	76.38	4.36	3.51	3.32	66.10	71.73



pressure at base of head or occipital nerve									
Dry eyes	806	15.61	26.70	91.38	3.16	2.32	1.99	74.81	54.59
Low blood oxygen	771	14.93	14.27	70.27	3.61	3.30	3.18	54.22	58.75
Muscle twitching	769	14.89	38.26	81.27	2.92	2.32	2.21	68.14	79.32
Postnasal drip	753	14.58	15.95	84.71	2.77	1.80	1.75	67.60	53.25
Mid-back pain at base of ribs	738	14.29	25.37	77.93	4.05	3.09	2.91	63.01	63.96
Nerve sensations	707	13.69	33.67	96.53	3.72	2.89	2.81	76.38	74.82
Floater or flashes of light in vision	701	13.58	39.59	83.56	2.67	2.38	2.06	74.04	72.18
Costochondritis	676	13.09	27.94	83.63	4.11	3.10	2.93	67.01	60.06
Cold burning feeling in lungs	674	13.05	14.58	79.46	3.93	3.13	3.07	64.39	70.62
Dry throat	665	12.88	14.70	80.51	3.26	2.24	2.14	68.42	58.80
Foot pain	655	12.69	40.76	81.84	3.80	2.72	2.62	80.61	68.09
Upper back pain	641	12.42	23.95	86.36	4.03	3.17	3.02	69.11	62.25
Cracked or dry lips	633	12.26	20.24	68.34	2.60	1.46	1.46	60.98	36.02
High blood pressure	627	12.14	30.04	80.68	2.89	2.55	2.41	68.58	55.34
Dry or peeling skin	614	11.89	32.76	73.58	2.42	1.56	1.55	66.61	29.97
Mouth sores or sore tongue	586	11.35	39.28	53.78	3.30	1.84	1.85	46.93	47.10
Feeling of burning skin	579	11.21	31.95	74.25	3.69	2.59	2.49	60.28	72.54
Swollen hands or feet	559	10.83	39.19	84.32	3.35	2.62	2.40	73.35	63.69

Swollen lymph nodes	541	10.48	26.36	70.28	3.12	2.07	1.98	52.87	43.81
Hot blood rush	537	10.40	29.53	85.68	3.34	2.38	2.36	70.02	80.63
Low temperature	510	9.88	17.76	61.99	2.39	1.82	1.87	53.33	68.63
Bilateral neck throbbing around lymph nodes	489	9.47	24.85	74.52	3.66	2.58	2.54	68.92	74.03
Irregular or skipped menstrual cycles	476	9.22	29.31	85.40	2.50	1.79	1.84	66.39	42.44
Jaw pain	473	9.16	39.07	66.02	3.63	2.30	2.20	58.14	67.23
Covid toes	452	8.75	35.32	57.07	3.00	1.96	1.85	50.00	44.91
Spikes in blood pressure	436	8.44	29.12	86.03	3.25	2.98	2.76	63.53	74.77
Bulging veins	429	8.31	53.59	80.67	2.36	1.84	1.75	73.43	62.00
GERD with excessive salivation	420	8.13	33.96	92.54	3.80	2.68	2.70	77.38	65.48
Painful scalp	383	7.42	40.73	64.69	3.35	2.04	2.02	54.57	57.96
Menstrual cycles that are heavier or lighter than usual	381	7.38	33.23	88.32	3.09	2.22	2.24	69.55	44.88
Kidney pain	379	7.34	33.56	57.00	3.86	2.74	2.60	49.34	67.28
Eye stye or infection	368	7.13	39.06	39.26	3.28	2.12	1.93	33.70	32.61
Dry scalp or dandruff	313	6.06	37.44	92.06	2.64	1.56	1.71	79.23	28.75
Goiter or lump in throat	296	5.73	33.40	84.46	3.57	2.45	2.37	65.54	50.68
UTI (urinary tract infection)	279	5.40	48.31	35.25	3.87	2.75	2.74	31.54	38.71

Low blood pressure	263	5.09	31.64	69.13	3.21	2.92	2.77	61.22	59.70
Kidney issues or protein in urine	256	4.96	40.34	66.19	3.28	2.58	2.51	58.59	37.89
Herpes	248	4.80	41.69	58.24	3.60	2.71	2.68	52.82	50.40
Personality change (drastic)	229	4.44	32.90	96.33	3.78	3.69	3.98	68.12	48.91
Thrush	226	4.38	38.76	50.61	3.00	1.95	2.05	33.63	30.09
Syncope	213	4.13	33.98	43.92	4.27	3.29	3.15	38.03	62.44
Hormone imbalances	202	3.91	38.22	99.07	3.42	2.82	2.88	68.32	45.54
Anemia	169	3.27	37.69	77.19	3.00	3.01	2.90	73.96	23.67
Elevated thyroid	141	2.73	52.75	88.52	3.02	2.67	2.52	68.79	17.73



**Figure 1** Percentage of respondents reporting each COVID-19 symptom






Figure 2 COVID-19 average symptom onset and duration



**Figure 3** The symptoms of PASC and their impact on survivors' ability to work



**Supplemental Figure 1** Number of COVID-19 symptoms experienced by PASC survivors